Emerald Advisers’s ARK Genomic Revolution ETF ARKG Stock Holding History

Emerald Advisers’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,696	Closed	-$47.9K	–	217
2022 Q4	$47.9K	Hold	1,696	–	–	﹤0.01%	218
2022 Q3	$56K	Hold	1,696	–	–	﹤0.01%	221
2022 Q2	$53K	Hold	1,696	–	–	﹤0.01%	228
2022 Q1	$78K	Hold	1,696	–	–	﹤0.01%	230
2021 Q4	$104K	Buy	+1,696	New	+$117K	﹤0.01%	240
2021 Q3	–	Sell	-1,696	Closed	-$157K	–	244
2021 Q2	$157K	Buy	+1,696	New	+$144K	0.01%	237
2021 Q1	–	Sell	-1,696	Closed	-$158K	–	249
2020 Q4	$158K	Buy	1,696 +343	+25%	+$27.3K	0.01%	238
2020 Q3	$86K	Hold	1,353	–	–	﹤0.01%	243
2020 Q2	$71K	Buy	+1,353	New	+$58K	﹤0.01%	242

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Emerald Advisers's ARKG Position: Q1 2023 in Review

Emerald Advisers sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2023, closing a stake of 1,696 shares — an estimated $47.9K sold.

Emerald Advisers first reported a position in ARKG in Q2 2020 and held it in 9 quarters. The position peaked at $158K in Q4 2020. 295 funds tracked by Wall St. Rank hold ARKG as of Q1 2023.

Emerald Advisers reported no remaining ARK Genomic Revolution ETF position as of Q1 2023 after selling out during the quarter.
Emerald Advisers sold 1,696 ARK Genomic Revolution ETF shares in Q1 2023, an estimated $47.9K.
Emerald Advisers first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 9 quarters.
Emerald Advisers's ARK Genomic Revolution ETF position peaked at $158K in Q4 2020.
295 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2023.

Based on Emerald Advisers's 13F filing for Q1 2023, filed 4 May 2023.